Oligonucleotide therapeutic development: Pre-clinical and translational considerations

In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including proteins, oligonucleotides, viral vectors, and engineered cells. One area within Complex Biologics experiencing tremendous growth is oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range of diseases.

Certara supported the first FDA approval of an oligonucleotide therapy as well as 23 subsequent programs. Watch this video to learn what pre-clinical and translational considerations oligonucleotide drug developers need to account for.